A more recent study revealed that blockade of mTOR with sapanisertib, which inhibits mTORC1 and mTORC2, with histone deacetylase (HDAC) inhibition is selectively toxic to Ras pathway-driven tumors, including human MPNST xenografts and the NPCis GEM model, by converging on the TXNIP/thioredoxin pathway [52]. Here, MTOR is linked to malignant peripheral nerve sheath tumor.